Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Squamous Cell Carcinoma of Head and Neck 7Oropharyngeal Neoplasms 7Carcinoma 6Lung Neoplasms 5Nasopharyngeal Carcinoma 4Mouth Neoplasms 4Laryngeal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Mesothelioma, Malignant 3Lymphoid Interstitial Pneumonia 3Hypopharyngeal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Ganglioneuroblastoma 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Tongue Neoplasms 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Medulloblastoma 1Locally Advanced Cervical Adenocarcinoma 1Liver Neoplasms 1

Interventions

Cisplatin 12Gemcitabine 9Specimen Handling 6Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Drug Therapy 5toripalimab 4Platinum 4Nivolumab 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3Radiotherapy 3Immune Checkpoint Inhibitors 3sintilimab 2Ipilimumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2tislelizumab 1relatlimab 1pembrolizumab 1olaparib 1fluciclovine F-18 1dehydroftorafur 1cemiplimab 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡